Spinraza carries a list price of $750,000 for the first year of treatment and $375,000 per year for every year after that. Because Spinraza is not a one-time treatment, costs accumulate significantly over a patient’s lifetime, potentially reaching millions of dollars within a decade.
First-Year and Ongoing Costs
The first year of Spinraza is the most expensive because it requires a series of loading doses to build up the drug in the spinal fluid. During those initial 12 months, patients receive up to six injections. After that, the schedule drops to three injections per year for maintenance, which is why the annual cost falls to roughly $375,000 from year two onward.
These figures represent the wholesale list price, sometimes called the WAC price. The actual amount paid by insurers, hospitals, or government programs is often lower due to negotiated discounts and rebates that are not publicly disclosed. For context, the Veterans Affairs Federal Supply Schedule price for a single vial of Spinraza is about $133,237, substantially below the commercial list price per dose.
Administration and Hospital Fees
The drug price alone doesn’t capture the full picture. Each dose of Spinraza is delivered through a lumbar puncture (a needle inserted into the lower spine), which requires a clinical visit and sometimes sedation or imaging guidance, particularly for patients with spinal fusion hardware or severe scoliosis. These facility and procedure fees add to the total cost of each treatment session.
A study tracking hospitalization costs found that among children receiving Spinraza, average per-patient hospital costs started around $22,903 and dropped to about $8,466 after the first year of treatment, a 63% decrease as clinicians and patients became more familiar with the procedure. Adults saw an even steeper decline, from roughly $14,000 to about $2,900 per patient. Emergency-related costs also fell by about 35%. So while each injection carries administrative overhead, that overhead tends to shrink over time.
Insurance and Medicare Coverage
Most patients do not pay the full list price out of pocket. Spinraza is covered under Medicare Part B as a physician-administered drug, provided it is prescribed for an FDA-approved indication of spinal muscular atrophy. Medicare limits reimbursement to six injections in the first 12 months and three injections in each subsequent 12-month period, matching the standard dosing schedule. Private insurers generally follow similar coverage patterns, though approval criteria and cost-sharing vary by plan.
Even with insurance, copays and coinsurance on a drug this expensive can be substantial. A 20% coinsurance on a $125,000 dose, for example, would leave a patient responsible for $25,000 per injection before hitting out-of-pocket maximums.
Financial Assistance Programs
Biogen, the company that makes Spinraza, offers a copay assistance program that can reduce out-of-pocket costs to as low as $0 for eligible patients with commercial insurance. Enrollment remains open for as long as you continue treatment, provided you still meet the eligibility criteria.
There are important exclusions. Patients covered by Medicare, Medicaid, Veterans Affairs, Department of Defense plans, or any other federal insurance programs are not eligible for the copay program. For those patients, Biogen’s support team can provide referrals to third-party charitable organizations that may help cover remaining costs.
How Spinraza Compares to Other SMA Treatments
Spinraza is one of three approved treatments for spinal muscular atrophy, and each has a very different pricing structure.
- Zolgensma is a one-time gene therapy infusion with a list price of approximately $2.1 million. Because it is a single treatment, there are no ongoing drug costs, but it is only approved for children under two years old. Over a lifetime, its total cost may be lower than decades of Spinraza injections.
- Evrysdi is a daily liquid medication taken by mouth at home. The VA Federal Supply Schedule price runs about $11,589 for a supply of oral suspension, making it significantly less expensive on a per-unit basis. It avoids the hospital visits and lumbar punctures Spinraza requires, but it is a lifelong daily medication.
The right comparison depends on the patient’s age, SMA type, and insurance situation. A child diagnosed at birth might be a candidate for a one-time Zolgensma infusion. An older child or adult who cannot receive gene therapy might weigh the convenience of daily Evrysdi against the established track record of Spinraza. Cost is one factor among several, and negotiated insurance rates can shift the math considerably.
Pricing Outside the United States
Spinraza’s cost varies internationally. In the United Kingdom, the first-year price was reported at roughly £450,000 (about $573,000 at the time), already lower than the U.S. list price. Even at that reduced figure, Britain’s cost-effectiveness body initially concluded that Spinraza was too expensive for the National Health Service, even with an additional confidential discount offered by Biogen. Several countries have since negotiated undisclosed price reductions to secure access. These international benchmarks suggest the effective price paid by large health systems is meaningfully below the U.S. sticker price, though the exact figures remain confidential.